Healthcare
Live Price
Offline$0.0241
+7.20% today
Window Change
+21.21%
Window
May 4, 2026 โ Jun 24, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 37 bars ยท May 4, 2026 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Botanix Pharmaceuticals Limited (BXPHF) is a Healthcare stock with a market cap of $50.00M. The stock last traded around $0.02 and up 21.2% across the available one-year price window (May 4, 2026 โ Jun 24, 2026). Baseline metrics include revenue growth of +178.2%, EPS growth of -408.7%, a dividend yield of 0.0%. What stands out right now is revenue +178.2%, EPS -408.7%, free cash flow -204.8% with operating margin -380.6% and ROIC -99.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BXPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+178.2% vs +7.6% peer median
Operating Margin
Below sector median
-380.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 27, 2026 with an EPS surprise of -69.1% and a revenue surprise of +0.0%.
The operating picture looks softer than before
Revenue is at +178.2% and EPS is at -408.7%, with operating margin around -380.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 28, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BXPHF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BXPHF Max Drawdown
-64.86%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BXPHF and SPY.
Company Overview
Botanix Pharmaceuticals Limited
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.